The atypical chemokine receptor D6 suppresses the development of chemically induced skin tumors

被引:128
作者
Nibbs, Robert J. B. [1 ]
Gilchrist, Derek S.
King, Vicky
Ferra, Antonio
Forrow, Steve
Hunter, Keith D.
Graham, Gerard J.
机构
[1] Univ Glasgow, Ctr Biomed Res, Div Immunol Infect & Inflammat, Glasgow, Lanark, Scotland
[2] Beatson Inst Canc Res, CR UK Beatson Labs, Glasgow G61 1BD, Lanark, Scotland
[3] Univ Glasgow, Glasgow Dent Sch, Glasgow, Lanark, Scotland
关键词
D O I
10.1172/JCI30068
中图分类号
R-3 [医学研究方法]; R3 [基础医学];
学科分类号
1001 ;
摘要
A subset of CC chemokines, acting through CC chemokine receptors (CCRs) 1 to 5, is instrumental in shaping inflammatory responses. Recently, we and others have demonstrated that the atypical chemokine receptor D6 actively sequesters and destroys many of these proinflammatory CC chemokines. This is critical for effective resolution of inflammation in vivo. Inflammation can be protumorigenic, and proinflammatory CC chemokines have been linked with various aspects of cancer biology, yet there is scant evidence supporting a critical role for these molecules in de novo tumor formation. Here, we show that D6-deficient mice have increased susceptibility to cutaneous tumor development in response to chemical carcinogenesis protocols and, remarkably, that D6 deletion is sufficient to make resistant mouse strains susceptible to invasive squamous cell carcinoma. Conversely, transgenic D6 expression in keratinocytes dampens cutaneous inflammation and can confer considerable protection from tumor formation in susceptible backgrounds. Tumor susceptibility consistently correlated with the level of recruitment of T cells and mast cells, cell types known to support the development of skin tumors in mice. These data demonstrate the importance of proinflammatory CC chemokines in de novo tumorigenesis and reveal chemokine sequestration by D6 to be a novel and effective method of tumor suppression.
引用
收藏
页码:1884 / 1892
页数:9
相关论文
共 49 条
  • [21] The chemokine receptor D6 limits the inflammatory response in vivo
    Jamieson, T
    Cook, DN
    Nibbs, RJB
    Rot, A
    Nixon, C
    Mclean, P
    Alcami, A
    Lira, SA
    Wiekowski, M
    Graham, GJ
    [J]. NATURE IMMUNOLOGY, 2005, 6 (04) : 403 - 411
  • [22] REDUCTION OF P53 GENE DOSAGE DOES NOT INCREASE INITIATION OR PROMOTION BUT ENHANCES MALIGNANT PROGRESSION OF CHEMICALLY-INDUCED SKIN TUMORS
    KEMP, CJ
    DONEHOWER, LA
    BRADLEY, A
    BALMAIN, A
    [J]. CELL, 1993, 74 (05) : 813 - 822
  • [23] Colony-stimulating factor 1 promotes progression of mammary tumors to malignancy
    Lin, EY
    Nguyen, AV
    Russell, RG
    Pollard, JW
    [J]. JOURNAL OF EXPERIMENTAL MEDICINE, 2001, 193 (06) : 727 - 739
  • [24] Chemokines in the recruitment and shaping of the leukocyte infiltrate of tumors
    Mantovani, A
    Allavena, P
    Sozzani, S
    Vecchi, A
    Locati, M
    Sica, A
    [J]. SEMINARS IN CANCER BIOLOGY, 2004, 14 (03) : 155 - 160
  • [25] Tuning inflammation and immunity by chemokine sequestration: decoys and more
    Mantovani, Alberto
    Bonecchi, Raffaella
    Locati, Massimo
    [J]. NATURE REVIEWS IMMUNOLOGY, 2006, 6 (12) : 907 - 918
  • [26] Mutually exclusive mutations of the Pten and ras pathways in skin tumor progression
    Mao, JH
    To, MD
    Perez-Losada, J
    Wu, D
    Del Rosario, R
    Balmain, A
    [J]. GENES & DEVELOPMENT, 2004, 18 (15) : 1800 - 1805
  • [27] Focus on head and neck cancer
    Mao, L
    Hong, WK
    Papadimitrakopoulou, VA
    [J]. CANCER CELL, 2004, 5 (04) : 311 - 316
  • [28] MARTINEZ DY, 2005, EUR J IMMUNOL, V35, P1342
  • [29] Immune activation and chronic inflammation as the cause of malignancy in oral lichen planus: is there any evidence
    Mignogna, MD
    Fedele, S
    Lo Russo, L
    Lo Muzio, L
    Bucci, E
    [J]. ORAL ONCOLOGY, 2004, 40 (02) : 120 - 130
  • [30] Macrophage inflammatory protein-1α as a costimulatory signal for mast cell-mediated immediate hypersensitivity reactions
    Miyazaki, D
    Nakamura, T
    Toda, M
    Cheung-Chau, KW
    Richardson, RM
    Ono, SJ
    [J]. JOURNAL OF CLINICAL INVESTIGATION, 2005, 115 (02) : 434 - 442